Healthcare Providers & Services

TradingKey - UnitedHealth beat Q2 2026 EPS by 30%, reported an 86.7% medical cost ratio (down from 89.4%), and raised full-year guidance to $19.50 to $20.00 per share. At $425 in a rising channel, here’s what $454 needs and why the DOJ investigation still matters.

TradingKey - Eli Lilly (LLY) shares rose nearly 2% in Thursday’s pre-market session as the market focused on a major decision from U.S. healthcare giant CVS Health (CVS). CVS announced it would restore insurance coverage for the weight-loss drug Zepbound and include Foundayo, an oral weight-loss medication newly approved in April, in its standard drug formulary.

TradingKey - Wall Street is navigating a two-day inflation gauntlet. Tuesday's CPI print for April arrived hotter than expected, rattling equity markets from telehealth to nuclear energy. Wednesday morning brings the Producer Price Index (PPI) for April — and if today's Consumer Price Index is any g

TradingKey - Hims & Hers Health (HIMS) is due to release its Q1 2026 results after the closing bell today. Below, we outline what investors should watch for in today's report.

TradingKey — This month, approximately 6 million people across the U.S. will begin receiving settlement payments averaging about $333 per person. The funds originate from a $2.67 billion antitrust class-action settlement involving the Blue Cross Blue Shield Association (BCBS), following more than a

UNH beat Q1 EPS by 10% at $7.23, MCR improved to 83.9%, and guidance raised to >$18.25. Stock jumped 8%. Key breakout level $357, targets $380–$407. Buy or wait?